Contineum Therapeutics, Inc. (CTNM) stock
Close on Nov 16, 2026Market cap $363.80MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $363.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.52
- Dividend yield
- –
- Free cash flow yield
- -14.70%
Fundamentals
- Net income
- -$57.56M
- EPS, diluted
- -$1.73
- Free cash flow
- -$53.46M
- Book value per share
- $6.40
- Diluted shares
- 37M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $9.86
- Open
- $9.67
- Day's range
- $9.46 – $9.93
- Volume
- 348,146
- Average volume (20 days)
- 562,296
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $6.72 – $17.79
- RSI (14 days)
- 46.8
- Volatility (1 year)
- 80.4%
- Relative volume
- 0.51×
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTNM | S&P 500 | Difference | CTNM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +36.6% | -3.1% | +39.6 pts | ||
| 3 months | -31.9% | -4.5% | −27.4 pts | ||
| Year to date | -15.4% | +9.4% | −24.8 pts | ||
| 1 year | -9.3% | +11.3% | −20.6 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Contineum Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Update
- Results
- Update
About Contineum Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical organization that discovers and develops small molecule therapeutics for neuro-inflammatory and immunological diseases. Its primary proprietary product candidate is PIPE-791, a brain-penetrant inhibitor of the lysophosphatidic acid 1 receptor under clinical investigation for idiopathic pulmonary fibrosis and chronic pain conditions such as osteoarthritis and lower back pain. The business also develops PIPE-307, a muscarinic type 1 receptor antagonist, in partnership with Johnson & Johnson for major depressive disorder and relapsing-remitting multiple sclerosis. It also conducts preclinical discovery targeting other related biological pathways.
Company profile, executives and historyContineum Therapeutics stock: common questions
What is Contineum Therapeutics's stock price?
CTNM closed at $9.67 on Nov 16, 2026, down 1.93% on the day. Over the past 52 weeks it traded between $6.72 and $17.79.
What is Contineum Therapeutics's market cap?
Contineum Therapeutics was worth $363.80M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is CTNM's P/E ratio?
Contineum Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.73), so it has no meaningful P/E ratio.
Does Contineum Therapeutics pay a dividend?
No. Contineum Therapeutics has not paid a cash dividend over the last twelve months.
When does Contineum Therapeutics report earnings next?
Contineum Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CTNM stock performed over the past year?
Including dividends, CTNM returned -9.3% over the past year, against +11.3% for the S&P 500.
How many CTNM shares are sold short?
4M shares were sold short at the latest FINRA report, 9.88% of the float, or 4.2 days of average trading volume.
Who are Contineum Therapeutics's competitors?
Companies most similar to Contineum Therapeutics by business, industry and size include DWTX, GRI, XENE, ANVS, PRAX.
See a number that looks wrong?